Start of sarcopenia clinical study reported

May 17, 2016

The latest research on natural astaxanthin was reported in the astaxanthin symposium sponsored by AstaReal Group, a global leader of natural astaxanthin supply in February, 2016 in Tokyo, Japan.  

 

The commencement of a randomized, double-blind, placebo-controlled clinical study with the AstaMed MYO formulation in sarcopenia patients at the University of Washington (UW), located in Seattle, WA was announced. In addition, a broad range of published and unpublished research on natural astaxanthin and chronic conditions and premature aging, including insulin resistance and neurological health areas, was also reported.  

 

“We are excited about the start of the sarcopenia clinical study at the University of Washington. We expect the forthcoming results of the study to demonstrate positive effects on sarcopenia measurements while identifying it as a manageable disease when an appropriate clinical strategy for its patients is adopted. Additional findings in the areas of insulin resistance and neurological health also showed promising trends and new hope for people living with associated conditions," said Dan Henry, General Manager of AstaMed.

 

 

*******

 

The relevant article posted at Nutritional Outlook:

http://www.nutritionaloutlook.com/science/astaxanthin-new-health-promises-horizon

 

About Sarcopenia

Sarcopenia is a disease that leads to the progressive loss of skeletal muscle. In sarcopenia, muscle mass decreases beyond the normal aging process because of inadequate lifestyle and other issues leading to decrease in muscle strength and/or physical performance, negatively impacting Quality of Life, mobility and independence, and even resulting in mortality. It has long been considered a part of aging that cannot be managed, even though it is estimated that sarcopenia affects approximately 45% of the U.S. senior population and exceeds $18 billion dollars in direct healthcare costs annually. Beginning October 1, 2016, sarcopenia will be coded in the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) under the code of M62.84.

 

About AstaMed® MYO
AstaMed MYO is a prescription medical food for the clinical dietary management of sarcopenia. The formulation consists of proprietary natural astaxanthin as well as natural tocotrienols, zinc and vitamin D3. The product is expected to be available in Q4' 2016 from pharmacies.

 

 

 

Please reload